$PCT
PureCycle Technologies, Inc. Stock $pct

$pct Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000183003321000008 Filed on May 19, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.624M	$1.238M
YoY Change	515.83%
% of Gross Profit
Research & Development	$547.0K	$348.0K
YoY Change	57.18%
% of Gross Profit
Depreciation & Amortization	$490.0K	$465.0K
YoY Change	5.38%
% of Gross Profit
Operating Expenses	$10.30M	$3.269M
YoY Change	215.11%
Operating Profit
YoY Change
Interest Expense	$2.043M	$588.0K
YoY Change	247.45%
% of Operating Profit
Other Income/Expense, Net	-$15.77M	-$1.295M
YoY Change	1117.99%
Pretax Income	-$30.12M	$0.00
YoY Change
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$26.07M	-$4.564M
YoY Change	471.3%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.51	-$0.19
Diluted Earnings Per Share	-$0.51	-$0.19
COMMON SHARES
Basic Shares Outstanding	51.22M shares	27.16M shares
Diluted Shares Outstanding	51.22M shares	27.16M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$252.5M	$100.0K
YoY Change	252400.0%
Cash & Equivalents	$252.5M	$3.109M
Short-Term Investments
Other Short-Term Assets	$6.800M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$259.3M	$100.0K
YoY Change	259240.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$108.4M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$317.5M	$100.0K
YoY Change	317400.0%
Total Long-Term Assets	$425.9M	$100.0K
YoY Change	425823.0%
TOTAL ASSETS
Total Short-Term Assets	$259.3M	$100.0K
Total Long-Term Assets	$425.9M	$100.0K
Total Assets	$685.3M	$200.0K
YoY Change	342531.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.481M	$0.00
YoY Change
Accrued Expenses	$18.45M	$0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$300.0K	$200.0K
YoY Change	50.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$30.63M	$200.0K
YoY Change	15213.0%
LONG-TERM LIABILITIES
Long-Term Debt	$289.0M	$0.00
YoY Change
Other Long-Term Liabilities	$24.30M
YoY Change
Total Long-Term Liabilities	$313.3M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.63M	$200.0K
Total Long-Term Liabilities	$313.3M	$0.00
Total Liabilities	$343.9M	$200.0K
YoY Change	171858.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$114.2M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$349.2M	$9.807M
YoY Change
Total Liabilities & Shareholders Equity	$685.3M	$200.0K
YoY Change	342531.5%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$26.07M	-$4.564M
YoY Change	471.3%
Depreciation, Depletion And Amortization	$490.0K	$465.0K
YoY Change	5.38%
Cash From Operating Activities	-$20.57M	-$4.919M
YoY Change	318.13%
INVESTING ACTIVITIES
Capital Expenditures	-$33.89M
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$33.89M	-$763.0K
YoY Change	4341.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$11.57M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$294.0M	$8.641M
YoY Change	3302.03%
NET CHANGE
Cash From Operating Activities	-$20.57M	-$4.919M
Cash From Investing Activities	-$33.89M	-$763.0K
Cash From Financing Activities	$294.0M	$8.641M
Net Change In Cash	$239.5M	$2.959M
YoY Change	7994.29%
FREE CASH FLOW
Cash From Operating Activities	-$20.57M	-$4.919M
Capital Expenditures	-$33.89M
Free Cash Flow	$13.32M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001830033
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	pct:AccountingStandardsUpdate2020-06
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Earnout Period Business Days Prior To Notice Of Redemption DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodBusinessDaysPriorToNoticeOfRedemption	P3D
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-40234
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	PureCycle Technologies, Inc.
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2293091
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5950 Hazeltine National Drive,
CY2021Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 650
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32822
CY2021Q1	dei	City Area Code CityAreaCode	877
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	648-3565
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	117349281	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	252549000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64492000	USD
CY2021Q1	us-gaap	Prepaid Royalties PrepaidRoyalties	4575000	USD
CY2020Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	2890000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2216000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	446000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	259340000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	67828000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	317535000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	266082000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	108388000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	70218000	USD
CY2021Q1	us-gaap	Assets Assets	685263000	USD
CY2020Q4	us-gaap	Assets Assets	404128000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1481000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1058000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18452000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26944000	USD
CY2021Q1	us-gaap	Interest Payable Current InterestPayableCurrent	10428000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4951000	USD
CY2021Q1	us-gaap	Notes Payable Current NotesPayableCurrent	265000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	122000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	30626000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33075000	USD
CY2021Q1	pct	Deferred Research And Development Obligation Noncurrent DeferredResearchAndDevelopmentObligationNoncurrent	1000000	USD
CY2020Q4	pct	Deferred Research And Development Obligation Noncurrent DeferredResearchAndDevelopmentObligationNoncurrent	1000000	USD
CY2021Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5000000	USD
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2021Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	57224000	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	26477000	USD
CY2021Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	231809000	USD
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	235676000	USD
CY2021Q1	pct	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	18258000	USD
CY2020Q4	pct	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	0	USD
CY2021Q1	us-gaap	Liabilities Liabilities	343917000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	296228000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	455475000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192381000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114246000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84563000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	341346000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	107900000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	685263000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	404128000	USD
CY2021Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2130000	USD
CY2020Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1683000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	547000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	348000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7624000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1238000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	10301000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	3269000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	6089000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	588000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	13621000	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	655000	USD
CY2021Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	109000	USD
CY2020Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	52000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19819000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1295000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-30120000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4564000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51223000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51223000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27156000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27156000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	107900000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	239000	USD
CY2021Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	36000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	307000	USD
CY2021Q1	pct	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	27900000	USD
CY2021Q1	pct	Stock Issued During Period Value Reverse Recapitalization Net Of Redemptions And Issuance Costs StockIssuedDuringPeriodValueReverseRecapitalizationNetOfRedemptionsAndIssuanceCosts	293966000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2021Q1	pct	Stock Reclassified During Period Value StockReclassifiedDuringPeriodValue	33000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	68000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-30120000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	341346000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	2380000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11574000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	417000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4564000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	9807000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-30120000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4564000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	417000	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	13621000	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	655000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	490000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	465000	USD
CY2021Q1	us-gaap	Accretion Expense AccretionExpense	57000	USD
CY2020Q1	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	784000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2021Q1	pct	Issuance Of Warrants Costs IssuanceOfWarrantsCosts	109000	USD
CY2020Q1	pct	Issuance Of Warrants Costs IssuanceOfWarrantsCosts	0	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1770000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	69000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Royalties IncreaseDecreaseInPrepaidRoyalties	1685000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Royalties IncreaseDecreaseInPrepaidRoyalties	0	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	423000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-78000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-987000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-13037000	USD
CY2021Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	5253000	USD
CY2020Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-758000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	5000000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20568000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4919000	USD
CY2021Q1	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	33891000	USD
CY2020Q1	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	763000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-33891000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-763000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	91000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	0	USD
CY2021Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2020Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	600000	USD
CY2021Q1	pct	Payments For Advance To Affiliate Financing PaymentsForAdvanceToAffiliateFinancing	0	USD
CY2020Q1	pct	Payments For Advance To Affiliate Financing PaymentsForAdvanceToAffiliateFinancing	2333000	USD
CY2021Q1	pct	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	298461000	USD
CY2020Q1	pct	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	0	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	480000	USD
CY2020Q1	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
CY2021Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4067000	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11574000	USD
CY2021Q1	pct	Payments For Redemption Of Vested Investments PaymentsForRedemptionOfVestedInvestments	36000	USD
CY2020Q1	pct	Payments For Redemption Of Vested Investments PaymentsForRedemptionOfVestedInvestments	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	293969000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8641000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	239510000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2959000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	330574000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	570084000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3109000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	456000	USD
CY2021Q1	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	16437000	USD
CY2020Q1	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	280000	USD
CY2021Q1	pct	Construction In Progress Expenditures Owed But Not Yet Paid ConstructionInProgressExpendituresOwedButNotYetPaid	224000	USD
CY2020Q1	pct	Construction In Progress Expenditures Owed But Not Yet Paid ConstructionInProgressExpendituresOwedButNotYetPaid	12000	USD
CY2021Q1	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2020Q1	us-gaap	Notes Issued1 NotesIssued1	661000	USD
CY2021Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	4604000	USD
CY2021Q1	pct	Reverse Recapitalization Merger Consideration Net ReverseRecapitalizationMergerConsiderationNet	1156900000	USD
CY2020Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	25000000.0	shares
CY2021Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.00
CY2021Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	250000000.0	USD
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Shares Maximum Issued DerivativeInstrumentContingentConsiderationLiabilitySharesMaximumIssued	4000000.0	shares
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	2000000.0	shares
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Earnout Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriod	P6M
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Earnout Period Stock Price Trigger DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger	18.00
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Earnout Period Threshold Trading Days DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays	20	employee
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Earnout Period Threshold Trading Day Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDayPeriod	30	employee
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	2000000.0	shares
CY2021Q1	pct	Adjustments To Additional Paid In Capital Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalRecapitalizationTransactionCosts	-27900000	USD
CY2021Q1	pct	Business Combination Acquisition Related Costs Advisory Legal And Accounting BusinessCombinationAcquisitionRelatedCostsAdvisoryLegalAndAccounting	5200000	USD
CY2021Q1	pct	Business Combination Acquisition Related Costs General And Administrative BusinessCombinationAcquisitionRelatedCostsGeneralAndAdministrative	3200000	USD
CY2021Q1	pct	Reverse Recapitalization Number Of Shares Transferred In Merger ReverseRecapitalizationNumberOfSharesTransferredInMerger	83500000	shares
CY2021Q1	pct	Reverse Recapitalization Shares Transferred In Merger Price Per Share ReverseRecapitalizationSharesTransferredInMergerPricePerShare	10.00
CY2021Q1	pct	Reverse Recapitalization Merger Consideration Transferred ReverseRecapitalizationMergerConsiderationTransferred	835000000	USD
CY2021Q1	pct	Reverse Recapitalization Merger Consideration Revenue Bonds ReverseRecapitalizationMergerConsiderationRevenueBonds	249600000	USD
CY2021Q1	pct	Reverse Recapitalization Merger Consideration Convertible Notes ReverseRecapitalizationMergerConsiderationConvertibleNotes	60000000	USD
CY2021Q1	pct	Reverse Recapitalization Merger Consideration Line Of Credit ReverseRecapitalizationMergerConsiderationLineOfCredit	314000	USD
CY2021Q1	pct	Reverse Recapitalization Merger Consideration Related Party Promissory Note ReverseRecapitalizationMergerConsiderationRelatedPartyPromissoryNote	12000000	USD
CY2021Q1	pct	Reverse Recapitalization Merger Consideration Net ReverseRecapitalizationMergerConsiderationNet	1156914000	USD
CY2021Q1	pct	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	76510000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	250000000	USD
CY2021Q1	pct	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	28049000	USD
CY2021Q1	pct	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	298461000	USD
CY2021Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	4600000	USD
CY2021Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	ReclassificationsCertain amounts in prior periods have been reclassified to conform with the report classifications of the three months ended March 31, 2021, noting the Company has reflected the reverse recapitalization pursuant to the Business Combination for all periods presented within the unaudited condensed consolidated balance sheets and statements of stockholders’ equity.
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	252500000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64500000	USD
CY2021Q1	pct	Working Capital WorkingCapital	228700000	USD
CY2020Q4	pct	Working Capital WorkingCapital	34800000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114200000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84600000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-30100000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4600000	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	26599000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192381000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-84563000	USD
CY2021Q1	pct	Reverse Recapitalization Conversion Price Quotient ReverseRecapitalizationConversionPriceQuotient	1000	USD
CY2021Q1	pct	Reverse Recapitalization Conversion Price Equity Value Threshold ReverseRecapitalizationConversionPriceEquityValueThreshold	775000000.0	USD
CY2021Q1	pct	Reverse Recapitalization Conversion Price Equity Value Threshold ReverseRecapitalizationConversionPriceEquityValueThreshold	775000000.0	USD
CY2021Q1	pct	Reverse Recapitalization Conversion Price ReverseRecapitalizationConversionPrice	6.93
CY2021Q1	pct	Reverse Recapitalization Conversion Shares ReverseRecapitalizationConversionShares	8660000	shares
CY2020Q4	pct	Reverse Recapitalization Conversion Price Quotient ReverseRecapitalizationConversionPriceQuotient	1000	USD
CY2020Q4	pct	Reverse Recapitalization Conversion Price Adjusted Equity Value Percent ReverseRecapitalizationConversionPriceAdjustedEquityValuePercent	0.80
CY2021Q1	pct	Debt Instrument Unforgiven Portion Payable Term DebtInstrumentUnforgivenPortionPayableTerm	P2Y
CY2021Q1	pct	Debt Instrument Unforgiven Portion Payable Payments Deferral Term DebtInstrumentUnforgivenPortionPayablePaymentsDeferralTerm	P10M
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000.0	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117350000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117350000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	0	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000.0	shares
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	613000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	28900
CY2021Q1	pct	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P7Y
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	613000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28900
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	0	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.41
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2021Q1	pct	Class Of Warrant Or Right Fair Value Assumptions Expected Dividend Rate ClassOfWarrantOrRightFairValueAssumptionsExpectedDividendRate	0
CY2021Q1	pct	Class Of Warrant Or Right Fair Value Assumptions Expected Volatility Rate ClassOfWarrantOrRightFairValueAssumptionsExpectedVolatilityRate	0.4851
CY2021Q1	pct	Class Of Warrant Or Right Fair Value Assumptions Risk Free Interest Rate ClassOfWarrantOrRightFairValueAssumptionsRiskFreeInterestRate	0.0056
CY2021Q1	pct	Class Of Warrant Or Right Fair Value Assumptions Expected Term ClassOfWarrantOrRightFairValueAssumptionsExpectedTerm	P3Y9M
CY2021Q1	pct	Class Of Warrant Or Right Fair Value Assumptions Expected Dividend Rate ClassOfWarrantOrRightFairValueAssumptionsExpectedDividendRate	0
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5900000	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	11.50
CY2021Q1	pct	Class Of Warrant Or Right Remaining Contractual Term ClassOfWarrantOrRightRemainingContractualTerm	P5Y
CY2021Q1	pct	Class Of Warrant Or Right Redemption Price Of Warrants Or Rights ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights	0.01
CY2021Q1	pct	Class Of Warrant Or Right Redemption Of Warrants Or Rights Written Notice Of Redemption Threshold ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsWrittenNoticeOfRedemptionThreshold	P30D
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Earnout Period Stock Price Trigger DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodStockPriceTrigger	18.00
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Earnout Period Threshold Trading Days DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDays	20	employee
CY2021Q1	pct	Derivative Instrument Contingent Consideration Liability Earnout Period Threshold Trading Day Period DerivativeInstrumentContingentConsiderationLiabilityEarnoutPeriodThresholdTradingDayPeriod	30	employee
CY2020Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	78000	USD
CY2021Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	78000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-30120000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4564000	USD
CY2021Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2020Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	730000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30120000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-30120000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5294000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	465000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5294000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51223000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51223000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27156000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27156000	shares
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	111678000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3290000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	108388000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	73018000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2800000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	70218000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	490000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	pct	Feedstock Supply Agreement Number Of Suppliers FeedstockSupplyAgreementNumberOfSuppliers	1	supplier
CY2020Q4	pct	Feedstock Supply Agreement Number Of Purchasers FeedstockSupplyAgreementNumberOfPurchasers	2	purchaser

Files In Submission

Name	View Source	Status
0001830033-21-000008-index-headers.html	Edgar Link	pending
0001830033-21-000008-index.html	Edgar Link	pending
0001830033-21-000008.txt	Edgar Link	pending
0001830033-21-000008-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
guarantyofcompletion-ex4.htm	Edgar Link	pending
guarantyofcompletion-ex4001.jpg	Edgar Link	pending
guarantyofcompletion-ex4002.jpg	Edgar Link	pending
guarantyofcompletion-ex4003.jpg	Edgar Link	pending
guarantyofcompletion-ex4004.jpg	Edgar Link	pending
guarantyofcompletion-ex4005.jpg	Edgar Link	pending
guarantyofcompletion-ex4006.jpg	Edgar Link	pending
guarantyofcompletion-ex4007.jpg	Edgar Link	pending
guarantyofcompletion-ex4008.jpg	Edgar Link	pending
guarantyofcompletion-ex4009.jpg	Edgar Link	pending
guarantyofcompletion-ex4010.jpg	Edgar Link	pending
guarantyofcompletion-ex4011.jpg	Edgar Link	pending
guarantyofcompletion-ex4012.jpg	Edgar Link	pending
guarantyofcompletion-ex4013.jpg	Edgar Link	pending
guarantyofcompletion-ex4014.jpg	Edgar Link	pending
guarantyofcompletion-ex4015.jpg	Edgar Link	pending
guarantyofcompletion-ex4016.jpg	Edgar Link	pending
guarantyofcompletion-ex4017.jpg	Edgar Link	pending
guarantyofcompletion-ex4018.jpg	Edgar Link	pending
guarantyofcompletion-ex4019.jpg	Edgar Link	pending
guarantyofcompletion-ex4020.jpg	Edgar Link	pending
guarantyofcompletion-ex4021.jpg	Edgar Link	pending
guarantyofcompletion-ex4022.jpg	Edgar Link	pending
guarantyofcompletion-ex4023.jpg	Edgar Link	pending
guarantyofcompletion-ex4024.jpg	Edgar Link	pending
guarantyofcompletion-ex4025.jpg	Edgar Link	pending
guarantyofcompletion-ex4026.jpg	Edgar Link	pending
guarantyofcompletion-ex4027.jpg	Edgar Link	pending
guarantyofcompletion-ex4028.jpg	Edgar Link	pending
guarantyofcompletion-ex4029.jpg	Edgar Link	pending
guarantyofcompletion-ex4030.jpg	Edgar Link	pending
guarantyofcompletion-ex4031.jpg	Edgar Link	pending
guarantyofcompletion-ex4032.jpg	Edgar Link	pending
guarantyofcompletion-ex4033.jpg	Edgar Link	pending
guarantyofcompletion-ex4034.jpg	Edgar Link	pending
guarantyofcompletion-ex4035.jpg	Edgar Link	pending
guarantyofcompletion-ex4036.jpg	Edgar Link	pending
guarantyofcompletion-ex4037.jpg	Edgar Link	pending
guarantyofcompletion-ex4038.jpg	Edgar Link	pending
guarantyofcompletion-ex4039.jpg	Edgar Link	pending
guarantyofcompletion-ex4040.jpg	Edgar Link	pending
guarantyofcompletion-ex4041.jpg	Edgar Link	pending
guarantyofcompletion-ex4042.jpg	Edgar Link	pending
guarantyofcompletion-ex4043.jpg	Edgar Link	pending
guarantyofcompletion-ex4044.jpg	Edgar Link	pending
guarantyofcompletion-ex4045.jpg	Edgar Link	pending
guarantyofcompletion-ex4046.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pct-20210331.htm	Edgar Link	pending
pct-20210331.xsd	Edgar Link	pending
pct-20210331_cal.xml	Edgar Link	unprocessable
pct-20210331_def.xml	Edgar Link	unprocessable
pct-20210331_g1.jpg	Edgar Link	pending
pct-20210331_htm.xml	Edgar Link	completed
pct-20210331_lab.xml	Edgar Link	unprocessable
pct-20210331_pre.xml	Edgar Link	unprocessable
pct-form10xqex311q12021.htm	Edgar Link	pending
pct-form10xqex312q12021.htm	Edgar Link	pending
pct-form10xqex321q12021.htm	Edgar Link	pending
pct-form10xqex322q12021.htm	Edgar Link	pending
pctsideletterex1010q1202.htm	Edgar Link	pending
pctsideletterex1010q1202001.jpg	Edgar Link	pending
pctsideletterex1010q1202002.jpg	Edgar Link	pending
pctsideletterex1010q1202003.jpg	Edgar Link	pending
pctsideletterex1010q1202004.jpg	Edgar Link	pending
purecycle-registrationrigh.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCT
PureCycle Technologies, Inc. Stock $pct

2021 Q1 Form 10-Q Financial Statement

#000183003321000008 Filed on May 19, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCT PureCycle Technologies, Inc. Stock $pct

2021 Q1 Form 10-Q Financial Statement

#000183003321000008 Filed on May 19, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCT
PureCycle Technologies, Inc. Stock $pct